Supernus Pharmaceuticals, Inc. announced Intangible asset impairment charges for the quarter ended December 31, 2023. For the quarter, the company reported Intangible asset impairment charges of $20,189,000.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
26.26 USD | -3.28% | -3.17% | -9.26% |
May. 23 | Supernus Pharmaceuticals Reports 'Clinical Utility' From Epilepsy Treatment Study | MT |
May. 23 | Transcript : Supernus Pharmaceuticals, Inc. - Special Call |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.26% | 1.44B | |
+18.88% | 80.5B | |
+14.11% | 9.15B | |
-14.14% | 4.9B | |
+43.39% | 4.49B | |
+18.90% | 4.44B | |
+7.93% | 2.19B | |
-28.40% | 2.13B | |
+15.93% | 2.1B | |
-43.17% | 1.78B |
- Stock Market
- Equities
- SUPN Stock
- News Supernus Pharmaceuticals, Inc.
- Supernus Pharmaceuticals, Inc. Announces Intangible Asset Impairment Charges for the Quarter Ended December 31, 2023